Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E M Alstead

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Gut|December 1, 1996
Ornithine decarboxylase activity is a marker of premalignancy in longstanding Helicobacter pylori infectionS E Patchett, P H Katelaris, Z W Zhang, et al.
Alimentary Pharmacology & Therapeutics|April 1, 1988
The effects of the 5-hydroxytryptamine (5HT3) receptor antagonist ICS 205-930 in the carcinoid syndromeM O Coupe, J V Anderson, J A Morris, et al.
Clinical Radiology|May 1, 1992
Proton NMR relaxation times in the normal human liver at 0.08 TS F Keevil, G Dolke, A P Brooks, et al.
Alimentary Pharmacology & Therapeutics|September 1, 1999
Early experience with intrasphincteric botulinum toxin in the treatment of achalasiaR R Greaves, H E Mulcahy, S E Patchett, et al.
Gut|June 9, 1998
Persistent systemic inflammatory response after stent insertion in patients with malignant bile duct obstructionA B Ballinger, J A Woolley, M Ahmed, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 1998
A prospective study of K-ras mutations in the plasma of pancreatic cancer patientsH E Mulcahy, J Lyautey, C Lederrey, et al.
Postgraduate Medical Journal|May 1, 1994
Pharmacokinetics of naftopidil, a novel anti-hypertensive drug, in patients with hepatic dysfunctionM J Farthing, E M Alstead, S M Abrams, et al.
Annals of the New York Academy of Sciences|May 20, 2000
Plasma DNA K-ras mutations in patients with gastrointestinal malignanciesH E Mulcahy, J Lyautey, C Lederrey, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Gut|December 1, 1996
Ornithine decarboxylase activity is a marker of premalignancy in longstanding Helicobacter pylori infectionS E Patchett, P H Katelaris, Z W Zhang, et al.
Alimentary Pharmacology & Therapeutics|April 1, 1988
The effects of the 5-hydroxytryptamine (5HT3) receptor antagonist ICS 205-930 in the carcinoid syndromeM O Coupe, J V Anderson, J A Morris, et al.
Clinical Radiology|May 1, 1992
Proton NMR relaxation times in the normal human liver at 0.08 TS F Keevil, G Dolke, A P Brooks, et al.
Alimentary Pharmacology & Therapeutics|September 1, 1999
Early experience with intrasphincteric botulinum toxin in the treatment of achalasiaR R Greaves, H E Mulcahy, S E Patchett, et al.
Gut|June 9, 1998
Persistent systemic inflammatory response after stent insertion in patients with malignant bile duct obstructionA B Ballinger, J A Woolley, M Ahmed, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 1998
A prospective study of K-ras mutations in the plasma of pancreatic cancer patientsH E Mulcahy, J Lyautey, C Lederrey, et al.
Postgraduate Medical Journal|May 1, 1994
Pharmacokinetics of naftopidil, a novel anti-hypertensive drug, in patients with hepatic dysfunctionM J Farthing, E M Alstead, S M Abrams, et al.
Annals of the New York Academy of Sciences|May 20, 2000
Plasma DNA K-ras mutations in patients with gastrointestinal malignanciesH E Mulcahy, J Lyautey, C Lederrey, et al.
Pageof 3